NeuroPace Shares Little Changed After FDA Greenlights AI Device
NeuroPace Inc. stock was flat in late trade Monday. The company got U.S. Food and Drug Administration approval for ECoG Assistant, its first AI tool aimed at epilepsy clinicians. The stock last changed hands at $16.49, down 0.3%. It moved between $15.68 and $16.73 today. Around 105,000 shares traded. The company’s market cap was about $556 million.